RWRichard J. Wakefield

Richard J. Wakefield

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Richard J. Wakefield has a total of 543 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Can Ultrasound Guide Treatment Decisions in Difficult‐to‐Treat Rheumatoid Arthritis?

    by Danila Madonna, Richard J. Wakefield, Emilio Filippucci, Kulveer Mankia, Shouvik Dass, Dennis McGonagle, Paul Emery, Andrea Di Matteo

  • Open Access

    The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring

    by Emilio D’IGnazio, Didem Sahin, Caterina Baldi, Paul Emery, Dennis McGonagle, Richard Wakefield, Helena Marzo-Ortega, Alen Zabotti, Emilio Filippucci, Katya Meridor, et al.

    Purpose of Review: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with highly heterogeneous clinical manifestations associated with psoriasis (PsO). The wide variability in presentation, together with the absence of definitive serological biomarkers, makes early diagnosis particularly challenging. This review evaluates the role of ultrasound in identifying and characterising musculoskeletal involvement across the psoriatic disease (PsD) continuum—from asymptomatic PsO to established PsA. Recent Findings: Ultrasound can detect subclinical synovitis, enthesitis, peritendonitis, tenosynovitis, bursitis, and structural damage in PsD. Evidence highlights its value in the early identification of musculoskeletal changes in patients with PsO who are at risk of progressing to PsA, with important implications for disease interception and prevention. Additional applications include differential diagnosis; assessment of enthesitis and distinction between inflammatory and non-inflammatory disease; and monitoring of therapeutic response, including in refractory disease. Ultrasound also demonstrates prognostic utility by detecting subclinical inflammation, predicting flares and future structural damage, and supporting personalized treatment strategies. Standardized ultrasound scoring systems and emerging methods for evaluating small hand entheses and dactylitis are also discussed. Summary: Ultrasound is an important tool for early detection, prognostic assessment, and management guidance in PsA, offering potential to prevent disease progression and inform precision medicine approach.


  • Open Access

    A systematic approach to the consensus definitions and reliability of ultrasound in idiopathic inflammatory myopathies; Preliminary data by the OMERACT ultrasound in myositis working group

    by Shereen Paramalingam, Jemima Albayda, Nens van Alfen, Fabio Becce, George A Bruyn, Edoardo Conticini, Louise Diederichsen, Kei Ikeda, Andrea Di Matteo, Ingrid Moller, et al.

  • Open Access

    The relationship between real-time ultrasound-detected extra-articular soft tissue pathologies and knee pain in osteoarthritis: a cross-sectional study

    by Asim Ghouri, Luke Budworth, Richard J. Wakefield, Sarah R. Kingsbury, Philip G. Conaghan

    Objective: Extra-articular soft tissue pathologies are relatively understudied in osteoarthritis (OA). We aimed to explore the relationship between structural pathology, sites of knee pain and knee pain severity, as determined using real-time ultrasound (US). Methods: Patients with painful knee OA received an US scan assessing a range of soft tissue structures at four quadrants (anterior, medial, lateral and posterior). US probe site tenderness (sono-palpation) was also assessed at each structure. Participants’ reported outcome measures were recorded, including sites of knee pain using the Knee Pain Map (using the same quadrant locations as structural pathology) and average numeric rating scale (NRS) for pain severity in the past week. Results: Fifty-four knees (26 men, BMI 31.5, mean NRS pain 5.4, 96% Kellgren–Lawrence 2/3) were included. Medial pain was the most frequently reported location. Semimembranosus tendon (SMT) hypoechogenicity, indicating tendinopathy, was the most frequent US finding (53%). However, there was no clear pattern between SMT pathology and knee pain location. Medial collateral ligament (MCL) and lateral collateral ligament (LCL) sono-palpation (reflecting clinical enthesitis) was more frequently observed in medial and lateral knee pain, respectively (43.2% and 52.9%). Higher NRS pain was significantly associated with MCL sono-palpation (1.41 NRS points; CI 0.47–2.36, p = 0.004) and Baker’s cyst sono-palpation (1.78 NRS points; CI 0.35–3.20, p = 0.016). A trend toward greater NRS pain was associated with US-detected patellar tendon pathology (1.1 NRS points; CI − 0.14–2.35, p = 0.08). Conclusion: This exploratory study highlighted the potential importance of extra-articular knee pathologies, particularly the collateral ligaments, in understanding OA knee pain location and severity. Key Points • This study measured the potential role of extra-articular pathology in OA knee pain. • Sono-palpation has been used as a novel method of measuring enthesitis. • Medial and lateral collateral ligament enthesitis may contribute to respective joint pain locations in knee OA. • Enthesitis may be secondary to biomechanical stresses around the knee joint.

  • Open Access

    Ultrasound-detected inflammation and structural changes in the joints, tendons and entheses of patients with cancer who developed arthritis or arthralgia after exposure to immune checkpoint inhibitors

    by Andrea Di Matteo, Kate Harnden, Sana Sharrack, Kerem Abacar, Didem Sahin, Tadashi Okano, Rudolf Horvath, Jana Hurnakova, Paraskevi V Voulgari, Melina Yerolatsite, et al.

    Objectives: To explore the prevalence and distribution of ultrasound-detected inflammation and structural damage in the joints, tendons and entheses of patients who developed new-onset arthritis or arthralgia following exposure to immune checkpoint inhibitor (ICI) therapy, including a comparison between those with ICI-induced arthritis and those with ICI-induced arthralgia. Methods: Patients with cancer who developed clinical arthritis or arthralgia (ie, joint pain without clinical synovitis) after receiving ICIs were consecutively recruited from six international centres. Patients underwent a full clinical assessment and ultrasound evaluation of 18 joints, 15 tendons and 5 entheses bilaterally, using the Outcome Measures in Rheumatology definitions. Results: A total of 101 patients were included: 53 (52.5%) had ICI-arthralgia (absent clinical synovitis). Among them, 25 (47.2%) had ultrasound-detected subclinical synovitis, 10 (18.9%) tenosynovitis, 1 (1.9%) digital extensor peritendinitis and 13 (24.5%) enthesitis. In the 48 patients with ICI-arthritis, ultrasound-detected synovitis was more prevalent than in ICI-arthralgia (93.8% vs 47.2%, p<0.001), particularly in the wrists (56.3% vs 20.8%, p<0.001) and the knees (54.2% vs 13.2%, p<0.001), which were the most frequently affected joints. Tenosynovitis (52.1% vs 18.9%, p<0.001), peritendinitis (10.4% vs 1.9%, p=0.099) and bone erosions (25% vs 7.5%, p=0.027) were also more frequent in ICI-arthritis. ‘Active’ enthesitis was similar between groups (31.3% vs 24.5%), with no significant differences. Conclusions: This multicentre study reveals a higher burden of ultrasound-detected changes in ICI-arthritis compared with ICI-arthralgia, with diverse patterns across joints, tendons and entheses in both subtypes. Significant subclinical inflammation suggests that many cases of non-specific ICI-arthralgia may benefit from targeted interventions.


  • Open Access

    Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritis

    by Stephanie Louise Smith, Vasileios Georgopoulos, Onosi Sylvia Ifesemen, Richard James, Eamonn Ferguson, Richard J. Wakefield, Deborah Wilson, Philip Buckley, Dorothy Platts, Susan Ledbury, et al.

    Introduction: The central nervous system (CNS) contributes to pain perception across musculoskeletal conditions. The central aspects of pain (CAP) questionnaire captures a single score associated with quantitative sensory testing (QST) evidence of CNS dysfunction validated in knee osteoarthritis. Objectives: Given the different pathophysiology of rheumatoid arthritis (RA), an inflammatory polyarthritis, this cross-sectional study assessed CAP's psychometric properties and its association with pain in RA. Methods: Adults with RA were recruited from Nottinghamshire, London, and Cardiff. Participants completed CAP and reported pain using a numerical rating scale. A subgroup underwent additional assessments, including quantitative sensory testing (QST; Pressure Pain detection Threshold, Temporal Summation, Conditioned Pain Modulation), Disease Activity Score-28, C-reactive protein, questionnaires addressing pain and related characteristics, and Central Sensitization Inventory short form (CSI-9). Cronbach alpha, confirmatory factor (CFA), and Rasch measurement theory assessed CAP's reliability and validity. Multivariable linear regression modelled contributions to pain by inflammation indices and CAP or CSI-9. Results: The 380 participants (73% female, median 63 years) reported average pain over the past 4 weeks of 6/10 and a CAP score of 9/16. Central aspects of pain demonstrated acceptable reliability (ICC(2,1) = 0.71), CFA fit (comparative fit index = 0.99, Tucker–Lewis index = 0.99, root mean square error of approximation = 0.034, standardized root mean residuals = 0.03), and internal consistency (α = 0.82). Central aspects of pain was significantly associated with pain (0.50 ≤ β ≤ 0.57) but not QST. Central aspects of pain explained 33% of pain variance, rising to 42% with inflammation, age, sex, and body mass index. Central Sensitization Inventory-9 correlated with pain, not QST and explained less pain variance than CAP. Conclusion: Central aspects of pain is reliable and valid for use with people with RA and explains RA pain variance better than inflammation or CSI-9.


  • Open Access

    Ultrasound Beyond Joints: A Review of Extra-Articular Applications in Rheumatology

    by Emilio D’iGnazio, Davide Corradini, Tomas Cazenave, Riccardo Bixio, Caterina Baldi, Harjit Kaur Ubhi, Kate Smith, Richard J. Wakefield, Paul Emery, Andrea Di Matteo

    Purpose of Review: This review highlights key ultrasound applications for evaluating extra-articular involvement in rheumatic diseases, including the lungs, vessels, salivary glands, muscles, nerves, skin, and nails. It explores recent advances, emerging areas of assessment, and future research directions. Additionally, the review examines current limitations in the routine use of ultrasound for these purposes and considers the potential of new technologies, such as shear-wave elastography, contrast-enhanced ultrasound, and artificial intelligence, to enhance the early detection and monitoring of extra-articular manifestations in rheumatic diseases. Recent Findings: Extra-articular manifestations in patients with rheumatic diseases are crucial for diagnosis, management (including treatment strategies), and prognosis, making accurate assessment essential. Growing evidence supports the role of ultrasound in assessing these manifestations for diagnosis, monitoring, and gaining insights into disease pathogenesis. Recent studies emphasize the significant utility of ultrasound in evaluating extra-articular involvement across various organ systems, including the lungs, vessels, salivary glands, muscles, nerves, skin, and nails. Technological advances, such as shear-wave elastography, contrast-enhanced ultrasound, and artificial intelligence, are expanding the scope and precision of ultrasound applications. Despite its potential, challenges such as operator dependency, lack of standardized protocols, and the need for specialized training hinder its widespread adoption. Summary: Ultrasound is a non-invasive, cost-effective, and radiation-free imaging modality with high diagnostic accuracy, making it a valuable tool for assessing extra-articular manifestations in rheumatic diseases. Emerging technologies may further enhance its clinical utility. However, efforts to standardize techniques and improve accessibility are necessary to optimize its integration into routine practice.


  • Open Access

    Undergraduate rheumatology teaching in the UK: a survey of current practice by teachers and students

    by Pippa Watson, David Hanna, Sophia M Wakefield, David Coady, Donna Andrew, Daisy Southam, Richard J Wakefield

    Objectives: The last major UK survey of medical undergraduate rheumatology teaching was 25 years ago. This study aimed to describe current teaching practice, the perceptions of teachers and students and their engagement with Versus Arthritis teaching resources and future challenges and opportunities. Methods: Electronic surveys were distributed by e-mail and/or social media to relevant teachers and students identified within all 37 UK medical schools. Results: A total of 34/37 (91%) teacher and 30/37 (81%) student surveys were returned. Compared with the last survey, the proportion of schools delivering rheumatology-identifiable teaching has fallen from 100% to 86% and the mean number of teaching days from 30 to 10. Rheumatology teaching is now more dispersed throughout the curriculum. Students preferred active learning methods such as simulation and expert patient teaching, while teachers preferred small-group teaching, online learning and lectures. The Versus Arthritis resources appeared underutilized by students but were considered useful. Most students thought rheumatology careers were not promoted within their medical school. Conclusion: A decrease in dedicated rheumatology teaching time was noted since the last survey 25 years ago. Greater promotion of rheumatology as a speciality and future career is required to maintain its professional identity and prevent marginalization.


  • Open Access

    Defining an Ageing-Related Pathology, Disease or Syndrome: International Consensus Statement

    by Emma Short, Ian M. Adcock, Bilal Al-Sarireh, Ann Ager, Ramzi Ajjan, Naveed Akbar, Michael A. Akeroyd, Ghada Alsaleh, Ghada Al-Sharbatee, Kambiz Alavian, et al.

    Background: Around the world, individuals are living longer, but an increased average lifespan does not always equate to an increased healthspan. With advancing age, the increased prevalence of ageing-related diseases can have a significant impact on health status, functional capacity, and quality of life. It is therefore vital to develop comprehensive classification and staging systems for ageing-related pathologies, diseases and syndromes. This will allow societies to better identify, quantify, understand, and meet the healthcare, workforce, wellbeing, and socioeconomic needs of ageing populations, while supporting the development and utilisation of interventions to prevent or to slow, halt or reverse the progression of ageing-related pathologies. Methods: The foundation for developing such classification and staging systems is to define the scope of what constitutes an ageing-related pathology, disease or syndrome. To this end, a consensus meeting was hosted by the International Consortium to Classify Ageing-Related Pathologies (ICCARP), on February 19 th , 2024, in Cardiff, UK, and was attended by 150 recognised experts. Discussions and voting were centred on provisional criteria that had been distributed prior to the meeting. The participants debated and voted on these. Each criterion required a consensus agreement of ≥70% for approval. Results: The accepted criteria for an ageing-related pathology, disease or syndrome were: Develops and/or progresses with increasing chronological age. Should be associated with, or contribute to, functional decline, or an increased susceptibility to functional decline. Evidenced by studies in humans. Conclusions: Criteria for an ageing-related pathology, disease or syndrome have been agreed by an international consortium of subject experts. These criteria will now be used by the ICCARP for the classification and ultimately staging of ageing-related pathologies, diseases and syndromes.


  • Open Access

    Possible rifampicin-induced arthritis in a patient receiving anti-tuberculosis therapy: the first reported case

    by Rahaymin Chowdhury, Nawaz Z Safdar, Deborah A B Ellames, Richard J Wakefield

    Dear Editor, R, a 76-year-old male undergoing treatment for pulmonary tuberculosis (TB), was referred to rheumatology by the infectious diseases team with suspected gout secondary to anti-tuberculous therapy. He was diagnosed with polymyalgia rheumatica (PMR) 6 years previously but was lost to follow-up and remained on long term low-dose prednisolone of varying doses. He also had prostate cancer with bony metastases; docetaxel chemotherapy was discontinued 9 months previously after only two cycles. Two days after starting rifampicin, isoniazid and pyrazinamide, R reported pain in multiple small and large joints, which was different in location and more severe to that experienced with his PMR. Prior to referral to us, R’s prednisolone had been increased from 6 mg/day to 15 mg/day but provided little relief. Physical examination revealed swelling over his metacarpophalangeal joints (MCPJ), metatarsophalangeal joints, the left wrist and ankle. Laboratory tests were negative for CCP, RF and ANA antibodies. CRP (25 mg/l) and ESR (59 mm/H) were elevated, with a leucocytosis (neutrophils 12.8 × 109/l, white cell count 14.6 × 109/l) possibly due to prednisolone use. Reduced albumin and haemoglobin were considered secondary to cancer and TB. Elevated serum urate (694 μmol/l) raised the suspicion of pyrazinamide-induced gout and pyrazinamide was ceased. R was discharged on a tapering dose of 20 mg prednisolone in addition to colchicine 500 μg tds. Ten days later, upon review by the rheumatology team, he was reporting ongoing significant pain in his hands, feet and knees alongside milder pain in the neck, right shoulder, groin and lower back despite normalization of serum urate (315 μmol/l). There was no reported improvement of symptoms since pyrazinamide cessation, with no previous history of gout. On examination, joint mobility was severely restricted due to pain. There was marked pitting oedema noted over the dorsum of both hands, MCPJ and ankles. An ultrasound (US) demonstrated low-level grey scale joint synovial thickening with increased power Doppler signal in his wrists and MCPJ ( Fig. 1) with similar changes seen around the deep flexor tendon sheaths of the wrist. Marked subcutaneous oedema was also noted over the dorsum of both hands and ankles. There was evidence of calcium pyrophosphate deposition (CPPD) bilaterally in the knee medial menisci but no specific features of gout or rheumatoid arthritis (RA); double contour, tophi or erosions were absent.